Department of Surgery, Eulji Medical Center, Daejeon, Republic of Korea.
Department of Pathology, Eulji Medical Center, Daejeon, Republic of Korea.
Pathol Res Pract. 2024 Oct;262:155531. doi: 10.1016/j.prp.2024.155531. Epub 2024 Aug 14.
Molecular studies have identified various treatment-related prognostic molecules to enhance the effectiveness of colorectal cancer (CRC) treatment and improve survival rates. The expression of cathepsin V in gastrointestinal cancer cells prompted an investigation into its potential as a prognostic indicator for CRC. The evaluation of cathepsin V expression and its clinicopathological significance was conducted through immunohistochemistry in a tissue microarray, encompassing 142 CRC and normal colorectal tissues. Overall and disease-free survival rates, based on cathepsin V expression levels, were assessed using the Kaplan-Meier method and compared utilizing the log-rank test. Univariate and multivariate analyses, employing a Cox proportional hazards model, were performed to identify prognostic factors. Cathepsin V expression exhibited no correlation with age, sex, tumor location, tumor size, or histological grade. However, it was significantly correlated with depth of tumor invasion, regional lymph node (LN) metastasis, distant metastasis, and lymphovascular involvement (all p<0.001). Overall and disease-free survival rates were significantly better with low cathepsin V expression than with high expression (p<0.001). Univariate analysis identified several prognostic factors, including histological grade (low vs. high), tumor size (≤ vs. >5 cm), tumor depth (T1 vs. ≥T2), regional LN metastasis, distant metastasis, tumor-node-metastasis (TNM) stage (Stage I vs ≥II), lymphovascular involvement, and cathepsin V expression. Multivariate analysis revealed that tumor depth, distant metastasis, and cathepsin V expression are independent predictors of poor survival. Cathepsin V is frequently expressed in CRC, and its high expression is associated with poor prognosis. Therefore, cathepsin V is a useful prognostic marker for CRC.
分子研究已经确定了各种与治疗相关的预后分子,以增强结直肠癌(CRC)治疗的效果并提高生存率。胃蛋白酶 V 在胃肠道癌细胞中的表达促使人们研究其作为 CRC 预后指标的潜力。通过免疫组织化学方法在组织微阵列中评估胃蛋白酶 V 的表达及其临床病理意义,该微阵列包括 142 例 CRC 和正常结直肠组织。根据胃蛋白酶 V 表达水平,使用 Kaplan-Meier 方法评估总生存率和无病生存率,并使用对数秩检验进行比较。使用 Cox 比例风险模型进行单因素和多因素分析,以确定预后因素。胃蛋白酶 V 表达与年龄、性别、肿瘤部位、肿瘤大小或组织学分级无关。然而,它与肿瘤浸润深度、区域淋巴结(LN)转移、远处转移和淋巴管侵犯显著相关(均 p<0.001)。低胃蛋白酶 V 表达的总生存率和无病生存率明显优于高表达(p<0.001)。单因素分析确定了几个预后因素,包括组织学分级(低 vs. 高)、肿瘤大小(≤ vs. >5 cm)、肿瘤深度(T1 vs. ≥T2)、区域 LN 转移、远处转移、肿瘤-淋巴结-转移(TNM)分期(I 期 vs. ≥II 期)、淋巴管侵犯和胃蛋白酶 V 表达。多因素分析显示,肿瘤深度、远处转移和胃蛋白酶 V 表达是不良生存的独立预测因素。胃蛋白酶 V 在 CRC 中常表达,其高表达与预后不良相关。因此,胃蛋白酶 V 是 CRC 的有用预后标志物。